Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) announced top-line results from the EMINENCE (Evaluation of M118 in Percutaneous Coronary Intervention) phase 2 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE